These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25716723)

  • 21. The causal relationship between epigenetic abnormality and cancer development: in vivo reprogramming and its future application.
    Yamada Y; Yamada Y
    Proc Jpn Acad Ser B Phys Biol Sci; 2018; 94(6):235-247. PubMed ID: 29887568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological mimicking of caloric restriction elicits epigenetic reprogramming of differentiated cells to stem-like self-renewal states.
    Oliveras-Ferraros C; Vazquez-Martin A; Menendez JA
    Rejuvenation Res; 2010 Oct; 13(5):519-26. PubMed ID: 21047255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 connects tumorigenesis and reprogramming to pluripotency.
    Tapia N; Schöler HR
    J Exp Med; 2010 Sep; 207(10):2045-8. PubMed ID: 20876313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reprogramming mammalian somatic cells.
    Rodriguez-Osorio N; Urrego R; Cibelli JB; Eilertsen K; Memili E
    Theriogenology; 2012 Dec; 78(9):1869-86. PubMed ID: 22979962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A medium-throughput analysis of signaling pathways involved in early stages of stem cell reprogramming.
    Fritz AL; Mao SR; West MG; Schaffer DV
    Biotechnol Bioeng; 2015 Jan; 112(1):209-19. PubMed ID: 25065366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Instant neurons: directed somatic cell reprogramming models of central nervous system disorders.
    Qiang L; Inoue K; Abeliovich A
    Biol Psychiatry; 2014 Jun; 75(12):945-51. PubMed ID: 24525100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of induced pluripotent stem cells from virus-free in vivo reprogramming of BALB/c mouse liver cells.
    de Lázaro I; Bussy C; Yilmazer A; Jackson MS; Humphreys NE; Kostarelos K
    Biomaterials; 2014 Sep; 35(29):8312-20. PubMed ID: 25002261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Genetic Cell Reprogramming: A New Technology for Basic Research and Applied Usage].
    Bogomazova AN; Vassina EM; Kiselev SI; Lagarkova MA; Lebedeva OS; Nekrasov ED; Panova AV; Philonenko ES; Khomyakova EA; Tskhovrebova LV; Chestkov IV; Shutova MV
    Genetika; 2015 Apr; 51(4):466-78. PubMed ID: 26087622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of reprogramming technology for cancer research].
    Yagi M; Semi K; Yamada Y
    Nihon Rinsho; 2015 May; 73(5):751-5. PubMed ID: 25985626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
    Kim JJ; Rai R
    Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concise review: non-cell autonomous reprogramming: a nucleic acid-free approach to induction of pluripotency.
    Parameswaran S; Balasubramanian S; Rao MS; Ahmad I
    Stem Cells; 2011 Jul; 29(7):1013-20. PubMed ID: 21544901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications.
    Sadahiro T; Yamanaka S; Ieda M
    Circ Res; 2015 Apr; 116(8):1378-91. PubMed ID: 25858064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY].
    Konno M; Ishii H; Doki Y; Mori M
    Nihon Geka Gakkai Zasshi; 2015 Nov; 116(6):357-9. PubMed ID: 26845886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic switching and cell fate decisions: implications for pluripotency, reprogramming and development.
    Cliff TS; Dalton S
    Curr Opin Genet Dev; 2017 Oct; 46():44-49. PubMed ID: 28662447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A roadmap for neurodevelopmental disease modeling for non-stem cell biologists.
    Ernst C
    Stem Cells Transl Med; 2020 May; 9(5):567-574. PubMed ID: 32052596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct Conversion Through Trans-Differentiation: Efficacy and Safety.
    Prasad A; Teh DB; Shah Jahan FR; Manivannan J; Chua SM; All AH
    Stem Cells Dev; 2017 Feb; 26(3):154-165. PubMed ID: 27796171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular reprogramming in skin cancer.
    Song IY; Balmain A
    Semin Cancer Biol; 2015 Jun; 32():32-9. PubMed ID: 24721247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular Pliancy and the Multistep Process of Tumorigenesis.
    Puisieux A; Pommier RM; Morel AP; Lavial F
    Cancer Cell; 2018 Feb; 33(2):164-172. PubMed ID: 29438693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cellular reprogramming to model and study epigenetic alterations in cancer.
    Kim J
    Stem Cell Res; 2020 Dec; 49():102062. PubMed ID: 33202305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How tumour cell identity is established?
    Sánchez-García I
    Semin Cancer Biol; 2015 Jun; 32():1-2. PubMed ID: 25931389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.